Relmada Therapeutics (RLMD) Accounts Payables (2012 - 2026)
Relmada Therapeutics (RLMD) reported Accounts Payables of $5.7 million for Q1 2026, up 353.07% year-over-year from $1.3 million in Q1 2025, and up 265.3% on a QoQ basis from $1.6 million in Q4 2025.
Relmada Therapeutics (RLMD) has 15 years of Accounts Payables data on file, last reported at $5.7 million in Q1 2026.
- Quarterly Accounts Payables rose 353.07% year-over-year to $5.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.7 million (up 353.07% YoY) and the FY2025 annual result came in at $1.6 million, down 62.02% from the prior year.
- Accounts Payables improved to $5.7 million in Q1 2026 per RLMD's latest filing, from $1.6 million in the prior quarter.
- Across five years, Accounts Payables topped out at $10.7 million in Q1 2022 and bottomed at $1.3 million in Q1 2025.
- The 5-year median for Accounts Payables is $4.2 million (2024), against an average of $4.5 million.
- The widest annual swing landed in 2025, when Accounts Payables sank 75.62%; it then surged 353.07% in 2026.
- Tracing RLMD's Accounts Payables over 5 years: stood at $5.3 million in 2022, then tumbled by 33.37% to $3.5 million in 2023, then increased by 17.81% to $4.1 million in 2024, then sank by 62.02% to $1.6 million in 2025, then soared by 265.3% to $5.7 million in 2026.
- Per Business Quant, the three latest RLMD Accounts Payables figures stand at $5.7 million (Q1 2026), $1.6 million (Q4 2025), and $1.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.05 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 83.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 10.62 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 8.64 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 489.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.03 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 126.63 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 5.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.73 Mn |
| Dec 31, 2025 | 1.57 Mn |
| Sep 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 1.27 Mn |
| Dec 31, 2024 | 4.13 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 4.17 Mn |
| Mar 31, 2024 | 5.19 Mn |
| Dec 31, 2023 | 3.51 Mn |
| Sep 30, 2023 | 2.86 Mn |
| Jun 30, 2023 | 4.85 Mn |
| Mar 31, 2023 | 4.42 Mn |
| Dec 31, 2022 | 5.26 Mn |
| Sep 30, 2022 | 10.43 Mn |
| Jun 30, 2022 | 7.54 Mn |
| Mar 31, 2022 | 10.67 Mn |
| Dec 31, 2021 | 11.19 Mn |
| Sep 30, 2021 | 12.71 Mn |
| Jun 30, 2021 | 10.46 Mn |
| Mar 31, 2021 | 8.08 Mn |
| Dec 31, 2020 | 8.35 Mn |
| Sep 30, 2020 | 728,633.00 |
| Jun 30, 2020 | 965,169.00 |
| Mar 31, 2020 | 1.10 Mn |
| Dec 31, 2019 | 522,663.00 |
| Sep 30, 2019 | 1.27 Mn |
| Jun 30, 2019 | 924,359.00 |
| Mar 31, 2019 | 1.08 Mn |
| Dec 31, 2018 | 358,892.00 |
| Sep 30, 2018 | 1.02 Mn |
| Jun 30, 2018 | 765,439.00 |
| Mar 31, 2018 | 1.09 Mn |
| Dec 31, 2017 | 286,056.00 |
| Sep 30, 2017 | 350,542.00 |
| Jun 30, 2017 | 529,558.00 |
| Mar 31, 2017 | 335,431.00 |
| Dec 31, 2016 | 307,235.00 |
| Sep 30, 2016 | 671,719.00 |
| Jun 30, 2016 | 1.26 Mn |
| Mar 31, 2016 | 744,160.00 |
| Dec 31, 2015 | 1.69 Mn |
| Sep 30, 2015 | 1.15 Mn |
| Jun 30, 2015 | 835,285.00 |
| Mar 31, 2015 | 390,371.00 |
| Dec 31, 2014 | 969,954.00 |
| Sep 30, 2014 | 624,733.00 |
| Jun 30, 2014 | 746,098.00 |
| Nov 30, 2013 | 40,331.00 |
| Aug 31, 2013 | 33,666.00 |
| May 31, 2013 | 25,751.00 |
| Feb 28, 2013 | 12,002.00 |
| Aug 31, 2012 | 6,996.00 |